Premium
Mucosal Administration of Completely Non‐Replicative Vaccinia Virus Recombinant Dairen I strain Elicits Effective Mucosal and Systemic Immunity
Author(s) -
Yoshino N.,
Kanekiyo M.,
Hagiwara Y.,
Okamura T.,
Someya K.,
Matsuo K.,
Ami Y.,
Sato S.,
Yamamoto N.,
Honda M.
Publication year - 2008
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2008.02168.x
Subject(s) - immunogenicity , nasal administration , virology , vaccinia , virus , antibody , biology , spleen , immunization , recombinant dna , immunology , immunity , simian immunodeficiency virus , recombinant virus , immune system , gene , biochemistry
We studied the immunogenicity of completely replication‐deficient vaccinia virus Dairen I strain recombinant encoding simian immunodeficiency virus (SIV) gag/pol (rDIs) in both mucosal and systemic compartments. When administered either intranasally or intragastrically, rDIs elicited enhanced levels of both SIV Gag p27‐specific IgA antibodies and specific plasma antibodies, and the enhanced immunity persisted for the 1‐year of observation by intranasal immunization. Increases were observed in antigen‐specific IgA antibody‐forming cells (AFC) in intestinal mucosal tissues and in IgG AFC in spleens. Furthermore, induction of type 1 and 2 helper cytokines in CD4 + spleen T cells and of CD8 + IFN‐γ spot‐forming cells in mucosal tissues was observed in the intranasally immunized mice. Moreover, not even high‐dose rDIs generated an SIV gene signal in the brain tissues of immunized mice. These findings suggest that mucosal immunization with the DIs recombinant hold promise as a safe mucosal vector.